BG62325B1 - Фармацевтичен състав за лечение на глаукома - Google Patents

Фармацевтичен състав за лечение на глаукома Download PDF

Info

Publication number: BG62325B1
Authority: BG; Bulgaria
Prior art keywords: amosulalol hydrochloride; eye; glaucoma; amosulalol; hydrochloride
Prior art date: 1992-05-22

Application number

BG99213A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG99213A (bg

Inventor

Takahiro Ogawa

Takaaki Deguchi

Yoshifumi Ikejiry

Katsuhiro Inada

Original Assignee

Senju Pharmaceutical Co.

Yamanouchi Pharmaceutical Co.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-22

Filing date

1994-11-28

Publication date

1999-08-31

1994-11-28 Application filed by Senju Pharmaceutical Co., Yamanouchi Pharmaceutical Co. filed Critical Senju Pharmaceutical Co.

1995-08-28 Publication of BG99213A publication Critical patent/BG99213A/bg

1999-08-31 Publication of BG62325B1 publication Critical patent/BG62325B1/bg

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
208000010412 Glaucoma Diseases 0.000 title claims description 43
150000003839 salts Chemical class 0.000 claims abstract description 11
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 9
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 9
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 9
239000004480 active ingredient Substances 0.000 claims abstract description 7
239000002253 acid Substances 0.000 claims abstract description 4
LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 claims description 80
239000002997 ophthalmic solution Substances 0.000 claims description 35
229940054534 ophthalmic solution Drugs 0.000 claims description 29
239000000203 mixture Substances 0.000 claims description 22
239000003795 chemical substances by application Substances 0.000 claims description 13
239000003885 eye ointment Substances 0.000 claims description 8
229940069265 ophthalmic ointment Drugs 0.000 claims description 7
239000002552 dosage form Substances 0.000 claims 2
229920000858 Cyclodextrin Polymers 0.000 abstract description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
229950010351 amosulalol Drugs 0.000 description 77
210000001508 eye Anatomy 0.000 description 77
235000002639 sodium chloride Nutrition 0.000 description 40
241000283973 Oryctolagus cuniculus Species 0.000 description 38
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
239000003814 drug Substances 0.000 description 32
239000011780 sodium chloride Substances 0.000 description 32
229940079593 drug Drugs 0.000 description 30
230000000694 effects Effects 0.000 description 29
239000007864 aqueous solution Substances 0.000 description 23
239000000243 solution Substances 0.000 description 21
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
210000001747 pupil Anatomy 0.000 description 15
238000012360 testing method Methods 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
238000005259 measurement Methods 0.000 description 10
239000003381 stabilizer Substances 0.000 description 9
238000009825 accumulation Methods 0.000 description 8
230000035508 accumulation Effects 0.000 description 8
WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 7
210000000795 conjunctiva Anatomy 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
229960005221 timolol maleate Drugs 0.000 description 7
239000000872 buffer Substances 0.000 description 6
230000008961 swelling Effects 0.000 description 6
238000011200 topical administration Methods 0.000 description 6
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 5
229940043377 alpha-cyclodextrin Drugs 0.000 description 5
229960000686 benzalkonium chloride Drugs 0.000 description 5
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
210000005252 bulbus oculi Anatomy 0.000 description 5
239000012530 fluid Substances 0.000 description 5
230000024883 vasodilation Effects 0.000 description 5
230000000007 visual effect Effects 0.000 description 5
238000005303 weighing Methods 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
239000002738 chelating agent Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
210000000744 eyelid Anatomy 0.000 description 4
230000004410 intraocular pressure Effects 0.000 description 4
239000013641 positive control Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
210000004087 cornea Anatomy 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
230000008014 freezing Effects 0.000 description 3
238000007710 freezing Methods 0.000 description 3
229940057995 liquid paraffin Drugs 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
231100001035 ocular change Toxicity 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
235000021055 solid food Nutrition 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000008399 tap water Substances 0.000 description 3
235000020679 tap water Nutrition 0.000 description 3
230000001256 tonic effect Effects 0.000 description 3
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
229930182837 (R)-adrenaline Natural products 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
230000002411 adverse Effects 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
229940030611 beta-adrenergic blocking agent Drugs 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
229960005139 epinephrine Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
208000018769 loss of vision Diseases 0.000 description 2
231100000864 loss of vision Toxicity 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000000034 method Methods 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
208000013441 ocular lesion Diseases 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
WPPDXAHGCGPUPK-UHFFFAOYSA-N red 2 Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=2C=3C4=CC=C5C6=CC=C7C8=C(C=9C=CC=CC=9)C9=CC=CC=C9C(C=9C=CC=CC=9)=C8C8=CC=C(C6=C87)C(C=35)=CC=2)C4=C1C1=CC=CC=C1 WPPDXAHGCGPUPK-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
235000011008 sodium phosphates Nutrition 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
231100000820 toxicity test Toxicity 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
230000004393 visual impairment Effects 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
JRVCPDVOFCWKAG-UHFFFAOYSA-N Amosulalol hydrochloride Chemical compound Cl.COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 JRVCPDVOFCWKAG-UHFFFAOYSA-N 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010018325 Congenital glaucomas Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012565 Developmental glaucoma Diseases 0.000 description 1
206010015946 Eye irritation Diseases 0.000 description 1
206010015958 Eye pain Diseases 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010050789 Hypochromasia Diseases 0.000 description 1
231100000111 LD50 Toxicity 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010043087 Tachyphylaxis Diseases 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940084882 alpha and beta blocking agent Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
208000003464 asthenopia Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
229960003612 bunazosin hydrochloride Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
231100000040 eye damage Toxicity 0.000 description 1
231100000013 eye irritation Toxicity 0.000 description 1
210000000720 eyelash Anatomy 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000005555 hypertensive agent Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
-1 methyl ethyl hydroxybenzoates Chemical class 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000002911 mydriatic effect Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
238000000399 optical microscopy Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
210000003786 sclera Anatomy 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
JWYQQWMDIXSRTH-UHFFFAOYSA-M sodium;hydroxy oxido hydrogen phosphate Chemical compound [Na+].OOP([O-])(=O)OO JWYQQWMDIXSRTH-UHFFFAOYSA-M 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000004575 stone Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BG99213A 1992-05-22 1994-11-28 Фармацевтичен състав за лечение на глаукома BG62325B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP13082892		1992-05-22
PCT/JP1993/000654 WO1993024121A1 (fr)	1992-05-22	1993-05-19	Medicament pour le glaucome

Publications (2)

Publication Number	Publication Date
BG99213A BG99213A (bg)	1995-08-28
BG62325B1 true BG62325B1 (bg)	1999-08-31

Family

ID=15043659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG99213A BG62325B1 (bg)	1992-05-22	1994-11-28	Фармацевтичен състав за лечение на глаукома

Country Status (14)

Country	Link
US (1)	US5663205A (de)
EP (1)	EP0642789B1 (de)
KR (1)	KR100253515B1 (de)
CN (1)	CN1080849A (de)
AT (1)	ATE185070T1 (de)
BG (1)	BG62325B1 (de)
BR (1)	BR9306399A (de)
CA (1)	CA2136321A1 (de)
DE (1)	DE69326610T2 (de)
ES (1)	ES2137260T3 (de)
HU (1)	HUT71123A (de)
RU (1)	RU2102069C1 (de)
TW (1)	TW219930B (de)
WO (1)	WO1993024121A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2737494B1 (fr) *	1995-08-04	1997-08-29	Synthelabo	Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
ID19891A (id) *	1996-08-02	1998-08-20	Senju Pharma Co	Komposisi gangguan peredaran anti-okular
US6379688B2 (en)	1997-02-28	2002-04-30	Senju Pharmaceutical Co., Ltd.	Preservative for emulsion and emulsion containing same
US6036946A (en) *	1997-12-24	2000-03-14	Shaklee Corporation	Methods for protecting skin from damaging effects of ultraviolet light
US6146664A (en) *	1998-07-10	2000-11-14	Shaklee Corporation	Stable topical ascorbic acid compositions
WO2000012137A1 (en) *	1998-09-02	2000-03-09	Allergan Sales, Inc.	Preserved cyclodextrin-containing compositions
US7867186B2 (en)	2002-04-08	2011-01-11	Glaukos Corporation	Devices and methods for treatment of ocular disorders
US7708711B2 (en)	2000-04-14	2010-05-04	Glaukos Corporation	Ocular implant with therapeutic agents and methods thereof
US7431710B2 (en)	2002-04-08	2008-10-07	Glaukos Corporation	Ocular implants with anchors and methods thereof
WO2002080811A2 (en)	2001-04-07	2002-10-17	Glaukos Corporation	Glaucoma stent and methods thereof for glaucoma treatment
US7678065B2 (en)	2001-05-02	2010-03-16	Glaukos Corporation	Implant with intraocular pressure sensor for glaucoma treatment
US7094225B2 (en)	2001-05-03	2006-08-22	Glaukos Corporation	Medical device and methods of use of glaucoma treatment
US7331984B2 (en)	2001-08-28	2008-02-19	Glaukos Corporation	Glaucoma stent for treating glaucoma and methods of use
US7163543B2 (en) *	2001-11-08	2007-01-16	Glaukos Corporation	Combined treatment for cataract and glaucoma treatment
US7951155B2 (en)	2002-03-15	2011-05-31	Glaukos Corporation	Combined treatment for cataract and glaucoma treatment
US9301875B2 (en)	2002-04-08	2016-04-05	Glaukos Corporation	Ocular disorder treatment implants with multiple opening
AU2003280812A1 (en) *	2002-11-18	2004-06-15	Santen Pharmaceutical Co., Ltd.	REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
WO2008055205A2 (en) *	2006-10-31	2008-05-08	Alcon Research, Ltd.	Pai-1 binding modulators for the treatment of ocular disorders
WO2008061043A2 (en)	2006-11-10	2008-05-22	Glaukos Corporation	Uveoscleral shunt and methods for implanting same
CZ2009190A3 (cs) *	2009-03-30	2010-10-13	Ústav experimentální medicíny AV CR, v.v.i	Zpusob merení lokální toxicity látek a zarízení k jeho provádení
US12478503B2 (en)	2009-05-18	2025-11-25	Glaukos Corporation	Implants with controlled drug delivery features and methods of using same
EP2432420A4 (de)	2009-05-18	2018-01-10	Dose Medical Corporation	Arzneimittelfreisetzendes augenimplantat
US10206813B2 (en)	2009-05-18	2019-02-19	Dose Medical Corporation	Implants with controlled drug delivery features and methods of using same
EP2654715B1 (de)	2010-11-24	2017-01-25	Dose Medical Corporation	Arzneimittelfreisetzendes augenimplantat
US11363951B2 (en)	2011-09-13	2022-06-21	Glaukos Corporation	Intraocular physiological sensor
US9163055B2 (en) *	2012-09-28	2015-10-20	Tufts University	Methods for treating glaucoma using uridine diphosphate derivatives
US9730638B2 (en)	2013-03-13	2017-08-15	Glaukos Corporation	Intraocular physiological sensor
WO2017040853A1 (en)	2015-09-02	2017-03-09	Glaukos Corporation	Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en)	2015-09-25	2017-03-30	Glaukos Corporation	Punctal implants with controlled drug delivery features and methods of using same
AU2017252294B2 (en)	2016-04-20	2021-12-02	Glaukos Corporation	Bioresorbable ocular drug delivery device

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3306820A (en) *	1966-03-18	1967-02-28	Barnes Hind Pharm Inc	Ophthalmic composition containing an anesthetic and fluorescein sodium
US4127674A (en) *	1977-03-21	1978-11-28	Allergan Pharmaceuticals, Inc.	Method of treatment for glaucoma
JPS5495544A (en) *	1977-12-23	1979-07-28	Yamanouchi Pharmaceut Co Ltd	Phenylethanolamine derivative and its preparation
CA1147342A (en) *	1977-10-12	1983-05-31	Kazuo Imai	Process of producing novel phenylethanolamine derivatives
JPS5746946A (en) *	1980-07-09	1982-03-17	Sandoz Ag	3-aminopropoxyphenyl derivative, manufacture and medicine containing same
DE3125870C2 (de) *	1980-07-09	1994-09-15	William John Louis	3-Aminopropoxyphenyl Derivate, ihre Herstellung und sie enthaltende Arzneimittel
IE51421B1 (en) *	1980-08-01	1986-12-24	Smith & Nephew Ass	Ophthalmic compositions containing triamterene
JPS6051106A (ja) *	1983-08-31	1985-03-22	Yamanouchi Pharmaceut Co Ltd	塩酸アモスラロ−ル持続性製剤
FR2640969B1 (de) *	1988-12-23	1991-11-22	Midy Spa
FR2642755B1 (de) *	1989-02-07	1993-11-05	Sanofi
JPH07508751A (ja) *	1992-07-02	1995-09-28	テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド	老視治療のための方法および生産品

1993
- 1993-05-19 EP EP93910356A patent/EP0642789B1/de not_active Expired - Lifetime
- 1993-05-19 AT AT93910356T patent/ATE185070T1/de not_active IP Right Cessation
- 1993-05-19 KR KR1019940704116A patent/KR100253515B1/ko not_active Expired - Fee Related
- 1993-05-19 DE DE69326610T patent/DE69326610T2/de not_active Expired - Fee Related
- 1993-05-19 BR BR9306399A patent/BR9306399A/pt not_active Application Discontinuation
- 1993-05-19 ES ES93910356T patent/ES2137260T3/es not_active Expired - Lifetime
- 1993-05-19 CA CA002136321A patent/CA2136321A1/en not_active Abandoned
- 1993-05-19 WO PCT/JP1993/000654 patent/WO1993024121A1/ja not_active Ceased
- 1993-05-19 RU RU94046143A patent/RU2102069C1/ru active
- 1993-05-19 US US08/338,592 patent/US5663205A/en not_active Expired - Fee Related
- 1993-05-20 TW TW082103976A patent/TW219930B/zh active
- 1993-05-21 CN CN93105941A patent/CN1080849A/zh active Pending
- 1993-05-22 HU HU9403350A patent/HUT71123A/hu unknown
1994
- 1994-11-28 BG BG99213A patent/BG62325B1/bg unknown

Also Published As

Publication number	Publication date
KR100253515B1 (ko)	2000-05-01
RU94046143A (ru)	1996-09-27
BR9306399A (pt)	1998-09-15
DE69326610D1 (de)	1999-11-04
EP0642789B1 (de)	1999-09-29
CN1080849A (zh)	1994-01-19
BG99213A (bg)	1995-08-28
HUT71123A (en)	1995-11-28
EP0642789A4 (de)	1995-03-29
CA2136321A1 (en)	1993-12-09
HU9403350D0 (en)	1995-02-28
DE69326610T2 (de)	2000-06-08
RU2102069C1 (ru)	1998-01-20
ATE185070T1 (de)	1999-10-15
EP0642789A1 (de)	1995-03-15
TW219930B (de)	1994-02-01
ES2137260T3 (es)	1999-12-16
WO1993024121A1 (fr)	1993-12-09
US5663205A (en)	1997-09-02

Publication	Publication Date	Title
EP0642789B1 (de)	1999-09-29	Arzneimittel gegen glaukom
US6403598B1 (en)	2002-06-11	Ophthalmic composition
JPWO1993024121A1 (ja)	1994-06-02	緑内障治療剤
US5527831A (en)	1996-06-18	Pharmaceutical composition for topical application to the eye for treating increased intraocular pressure
US9901580B2 (en)	2018-02-27	Methods of eye treatment using therapeutic compositions containing dipyridamole
US5196449A (en)	1993-03-23	Methods and pharmaceutical compositions for the treatment of ophthalmic diseases
US5519030A (en)	1996-05-21	Method for prophylaxis and treatment of myopia
TW304879B (de)	1997-05-11
Newsome	1989	Noninfectious ocular complications of AIDS
JP2741285B2 (ja)	1998-04-15	緑内障治療剤
Moore	2022	8 Chapter Anticholinergic Agents (Parasympatholytics)
WO2025140240A1 (zh)	2025-07-03	一种用于治疗和/或预防角膜损伤的药物组合物和方法
Gilger	0	Il glaucoma nel cavallo
Sampaolesi et al.	2013	Medical Therapy in Glaucoma
Michau	2008	How to diagnose and treat glaucoma in the horse.
HUP9903165A2 (hu)	2000-02-28	Amoszulalol alkalmazása a szem keringési zavarainak kezelésére alkalmas gyógyszerkészítmény előállítására